InspireMD's CGuard Prime Claims Lowest Adjudicated Adverse Event Rates in Pivotal Carotid Stenting Evidence
SHERIDAN, WYOMING - April 14, 2026 - InspireMD, a medical technology company specializing in vascular disease treatment and embolic protection, is positioning its CGuard Prime carotid stent system as a clinical performance benchmark in carotid artery stenting, citing independently adjudicated trial data showing a 0.95% composite major adverse event rate at 30 days and 1.93% at one year-figures the company characterizes as the lowest of any pivotal carotid stenting study to date. The device's dual-layer MicroNet™ mesh architecture directly targets late embolization through stent struts, a failure mode associated with approximately two-thirds of major adverse events following carotid artery stenting procedures according to published vascular surgery research. CGuard Prime carries FDA clearance for use in high-surgical-risk patients requiring carotid revascularization and is marketed across U.S. and international markets.